News

Regeneron Announces Positive Phase II Results for Evinacumab

Written by Yourway | September 10, 2019

In a trial evaluating patients with homozygous familial hypercholesterolemia, a genetically inherited form of increased LDL cholesterol, Regeneron’s drug showed a 49% decrease in LDL levels, compared with a 2% decrease for placebo. Yourway is dedicated to helping support clinical trials like this for rare disease patients.